Results 21 to 30 of about 238 (77)

Supplementary Table S6 from Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial

open access: yes, 2019
Table S6 shows the percentage of MHC class I positive cells in tumor tissue from NIBIT-M4 patients at baseline, at Week 4 and at Week 12.
Alessia Covre (6058937)   +26 more
core   +1 more source

Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study [PDF]

open access: yesJournal for ImmunoTherapy of Cancer, 2013
Meeting abstracts Ipilimumab (IPI) in combination with fotemustine (FTM) has shown a promising clinical activity in metastatic melanoma (MM) patients (pts) enrolled in the NIBIT-M1 trial (Di Giacomo, et al., Lancet Oncology, 2012).
Maccalli, Cristina   +9 more
openaire   +1 more source

Supplementary Table S7 from Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial

open access: yes, 2019
Table S7 describes the density of different cell type (CD8+ T cell, PD-1+ T cells and CD20+ B cell) in tumor core of samples from NIBIT-M4 patients at baseline, at Week 4 and at Week 12.
Alessia Covre (6058937)   +26 more
core   +1 more source

Supplementary Fig S2 from Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial

open access: yes, 2019
Figure shows density of CD20+ cells in the tumor core of NIBIT-M4 patients at different time points during treatment and the correlation between density and patients clinical ...
Alessia Covre (6058937)   +26 more
core   +1 more source

Supplementary Table S5 from Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial

open access: yes, 2019
Table S5 lists canonical pathways activated or inhibited in responding vs non-responding NIBIT-M4 patients at baseline, at Week 4 and at W12.
Alessia Covre (6058937)   +26 more
core   +1 more source

Supplementary Table S1 from Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial

open access: yes, 2019
Table S1 describes pharmacokinetic parameters (Tmax, time taken to reach peak concentration; Cmax, peak serum concentration; AUC, area under the curve) for decitabine and guadecitabine, by dose of guadecitabine in NIBIT-M4 patients.
Alessia Covre (6058937)   +26 more
core   +1 more source

Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial

open access: yes, 2020
Background Brain metastases (BM) represent a high-unmet medical need, in which the therapeutic potential of immune-checkpoint(s) (ICI) is being actively investigated. Temozolomide and fotemustine (FTM) have been the therapeutic mainstay of melanoma (MM)
Marchetti, P.   +50 more
core   +1 more source

Supplementary Table S4 from Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial

open access: yes, 2019
Table S4 lists canonical pathways that were modulated in tumor samples of NIBIT-M4 patients by treatment, and also describes the number of tumor samples in which the specific pathway was modulated ...
Alessia Covre (6058937)   +26 more
core   +1 more source

Cancer bio-immunotherapy XVI annual NIBIT-(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy

open access: yesCancer Immunology, Immunotherapy, 2020
Not ...
Bellone M   +15 more
openaire   +4 more sources

Karakteristik Mutu Fisiko-Kimia Sosis Fermentasi Daging Sapi [PDF]

open access: yes, 1999
Dalam penelitian ini, sosis yang dibuat merupakan campuran daging sapi, lemak sapi, garam kuring NPS (Nibit Poekelen Salz) dan bumbu-bumbu kemudian dibuat dalam bentuk cacaban dan dimasukan ke dslam selongsong sintetik berdiameter 21 mm selanjutnya ...
Sutardi, Budi Firmansyah
core   +1 more source

Home - About - Disclaimer - Privacy